Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

被引：1
|
作者：
Wang, Michael [1 ]
Jurczak, Wojciech [2 ]
Trneny, Marek [3 ]
Belada, David [4 ]
Wrobel, Tomasz [5 ]
Ghosh, Nilanjan [6 ]
Keating, Mary-Margaret [7 ]
van Meerten, Tom [8 ]
Fernandez Alvarez, Ruben [9 ]
von Keudell, Gottfried [10 ]
Thieblemont, Catherine [11 ]
Peyrade, Frederic [12 ]
Andre, Marc [13 ]
Hoffmann, Marc [14 ]
Glusman, Edith Szafer [15 ]
Lin, Jennifer [15 ]
Dean, James P. [15 ]
Neuenburg, Jutta K. [15 ]
Tam, Constantine S. [16 ,17 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA
[2] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland
[3] Gen Univ Hosp Prague, Prague, Czech Republic
[4] Charles Univ Prague, Dept Internal Med Haematol 4, Hosp & Fac Med, Hradec Kralove, Czech Republic
[5] Wroclaw Med Univ, Wroclaw, Poland
[6] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[7] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[8] Univ Med Ctr Groningen, Groningen, Netherlands
[9] Hosp Univ Cabuenes, Asturias, Spain
[10] Beth Israel Deaconess Med Ctr, Boston, MA USA
[11] Univ Paris, Hop St Louis, Assistance Publ Hop Paris, Serv Hematooncol, Paris, France
[12] Ctr Antoine Lacassagne, Nice, France
[13] CHU UCL Namur Mt Godinne, Yvoir, Belgium
[14] Univ Kansas, Ctr Canc, Kansas City, KS USA
[15] AbbVie, N Chicago, IL USA
[16] Alfred Hlth, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[17] Monash Univ, Melbourne, Vic, Australia
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2023-191921
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：LBA5 / LBA5
页数：1
相关论文
共 50 条
  • [41] ECONOMIC EVALUATION OF IBRUTINIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA IN MEXICO
    Carlos, F.
    Herrera, M.
    Salazar, A.
    Aguirre, A.
    Gonzalez-Michaca, L.
    VALUE IN HEALTH, 2016, 19 (03) : A249 - A249
  • [42] Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
    Dreyling, Martin
    Jurczak, Wojciech
    Jerkeman, Mats
    Silva, Rodrigo Santucci
    Rusconi, Chiara
    Trneny, Marek
    Offner, Fritz
    Caballero, Dolores
    Joao, Cristina
    Witzens-Harig, Mathias
    Hess, Georg
    Bence-Bruckler, Isabelle
    Cho, Seok-Goo
    Bothos, John
    Goldberg, Jenna D.
    Enny, Christopher
    Traina, Shana
    Balasubramanian, Sriram
    Bandyopadhyay, Nibedita
    Sun, Steven
    Vermeulen, Jessica
    Rizo, Aleksandra
    Rule, Simon
    LANCET, 2016, 387 (10020): : 770 - 778
  • [43] Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Kim, Austin I.
    Armand, Philippe
    Redd, Robert A.
    Forsyth, Megan
    Branch, Paul
    Pazienza, Samantha
    Brennan, Lisa
    Patterson, Victoria
    Waisgerber, Susan M.
    Merryman, Reid W.
    Fisher, David C.
    Ryan, Christine E.
    Ahn, Inhye E.
    Crombie, Jennifer L.
    Odejide, Oreofe O.
    LaCasce, Ann
    Jacobson, Caron A.
    Jacobsen, Eric
    Parry, Erin M.
    Davids, Matthew S.
    Brown, Jennifer R.
    Freedman, Arnold S.
    Riedell, Peter A.
    Murakami, Mark Alan
    BLOOD, 2023, 142
  • [44] A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma
    Kim, Myung Sun
    Banerjee, Titas
    Chen, Andy
    Danilov, Alexey
    MacKinnon, Renee
    Thurlow, Bria
    Thakurta, Sujata
    Orand, Kirsten
    Degnin, Catherine
    Park, Byung
    Spurgeon, Stephen E.
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 722 - 724
  • [45] OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY
    Visco, C.
    Di Rocco, A.
    Tisi, M.
    Morello, L.
    Evangelista, A.
    Zilioli, V. R.
    Rusconi, C.
    Hohaus, S.
    Sciarra, R.
    Re, A.
    Tecchio, C.
    Chiappella, A.
    Niebla, A. M.
    McCulloch, R.
    Gini, G.
    Perrone, T.
    Nassi, L.
    Pennese, E.
    Stefani, P. M.
    Cox, M. C.
    Bozzoli, V.
    Fabbri, A.
    Polli, V.
    Ferrero, S.
    De Celis, I. A.
    Sica, A.
    Arcaini, L.
    Balzarotti, M.
    Rule, S.
    Vitolo, U.
    HAEMATOLOGICA, 2019, 104 : 7 - 7
  • [46] Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study
    Carlo Visco
    Alice Di Rocco
    Andrea Evangelista
    Francesca Maria Quaglia
    Maria Chiara Tisi
    Lucia Morello
    Vittorio Ruggero Zilioli
    Chiara Rusconi
    Stefan Hohaus
    Roberta Sciarra
    Alessandro Re
    Cristina Tecchio
    Annalisa Chiappella
    Ana Marin-Niebla
    Rory McCulloch
    Guido Gini
    Tommasina Perrone
    Luca Nassi
    Elsa Pennese
    Piero Maria Stefani
    Maria Christina Cox
    Valentina Bozzoli
    Alberto Fabbri
    Valentina Polli
    Simone Ferrero
    Maria Isabel Alvarez De Celis
    Antonello Sica
    Luca Petrucci
    Luca Arcaini
    Simon Rule
    Mauro Krampera
    Umberto Vitolo
    Monica Balzarotti
    Leukemia, 2021, 35 : 787 - 795
  • [47] Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial
    Jerkeman, Mats
    Hutchings, Martin
    Raty, Riikka
    Wader, Karin Fahl
    Laurell, Anna
    Christensen, Jacob H.
    Kuitunen, Hanne
    Eskelund, Christian Winther
    Groenbaek, Kirsten
    Niemann, Carsten Utoft
    Geisler, Christian H.
    Kolstad, Arne
    BLOOD, 2020, 136
  • [48] Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial
    Jerkeman, Mats
    Hutchings, Martin
    Raty, Riikka
    Wader, Karin Fahl
    Laurell, Anna
    Kuitunen, Hanne
    Toldbod, Helle
    Pedersen, Lone Bredo
    Eskelund, Christian Winther
    Gronbaek, Kirsten
    Niemann, Carsten Utoft
    Geisler, Christian H.
    Kolstad, Arne
    BLOOD, 2016, 128 (22)
  • [49] Real-World Outcomes for Patients Treated with Ibrutinib for Relapsed/Refractory Mantle Cell Lymphoma in Denmark
    Trab, Trine
    Chanchiri, Iman
    Al-Mashhadi, Ahmed
    Berggreen, Emma
    Rasch, Stine
    Johansen, Mette
    Husby, Simon
    Clausen, Michael Roost
    Larsen, Thomas Stauffer
    Desseau-Arp, Andriette C.
    Christensen, Jacob Haaber
    Pedersen, Robert Schou
    Frederiksen, Mikael
    Brown, Peter de Nully
    El-Galaly, Tarec Christoffer
    Gronbaek, Kirsten
    BLOOD, 2024, 144 : 6325 - 6326
  • [50] Economic Evaluation of Ibrutinib Versus Acalabrutinib Versus Zanubrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Alrawashdh, Neda
    McBride, Ali
    Slack, Marion
    Abraham, Ivo
    BLOOD, 2020, 136
12345